论文部分内容阅读
Diabetes mellitus is one of the most common chronic disease in the world, CPRC 1 is a novel dipeptidylpeptidase-Ⅳ(DPP-4) inhibitor which was proposed to control hyperglycemia in patients with type 2 diabetes mellitus.CPRC1 just received Investigational New Drug (IND) approval from China Food and Drug Administration (CFDA) and is waiting for first-in-human study.In order to design its FIH study better, accurate prediction of effective dosage is critical.